These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
257 related articles for article (PubMed ID: 32359398)
1. Identification of a Structural Determinant for Selective Targeting of HDMX. Ben-Nun Y; Seo HS; Harvey EP; Hauseman ZJ; Wales TE; Newman CE; Cathcart AM; Engen JR; Dhe-Paganon S; Walensky LD Structure; 2020 Jul; 28(7):847-857.e5. PubMed ID: 32359398 [TBL] [Abstract][Full Text] [Related]
2. A stapled p53 helix overcomes HDMX-mediated suppression of p53. Bernal F; Wade M; Godes M; Davis TN; Whitehead DG; Kung AL; Wahl GM; Walensky LD Cancer Cell; 2010 Nov; 18(5):411-22. PubMed ID: 21075307 [TBL] [Abstract][Full Text] [Related]
3. Structural States of Hdm2 and HdmX: X-ray Elucidation of Adaptations and Binding Interactions for Different Chemical Compound Classes. Kallen J; Izaac A; Chau S; Wirth E; Schoepfer J; Mah R; Schlapbach A; Stutz S; Vaupel A; Guagnano V; Masuya K; Stachyra TM; Salem B; Chene P; Gessier F; Holzer P; Furet P ChemMedChem; 2019 Jul; 14(14):1305-1314. PubMed ID: 31066983 [TBL] [Abstract][Full Text] [Related]
4. Crystal Structures of Human MdmX (HdmX) in Complex with p53 Peptide Analogues Reveal Surprising Conformational Changes. Kallen J; Goepfert A; Blechschmidt A; Izaac A; Geiser M; Tavares G; Ramage P; Furet P; Masuya K; Lisztwan J J Biol Chem; 2009 Mar; 284(13):8812-21. PubMed ID: 19153082 [TBL] [Abstract][Full Text] [Related]
5. Functional profiling of p53-binding sites in Hdm2 and Hdmx using a genetic selection system. Datta S; Bucks ME; Koley D; Lim PX; Savinov SN Bioorg Med Chem; 2010 Aug; 18(16):6099-108. PubMed ID: 20638853 [TBL] [Abstract][Full Text] [Related]
6. N-acylpolyamine inhibitors of HDM2 and HDMX binding to p53. Hayashi R; Wang D; Hara T; Iera JA; Durell SR; Appella DH Bioorg Med Chem; 2009 Dec; 17(23):7884-93. PubMed ID: 19880322 [TBL] [Abstract][Full Text] [Related]
7. HDM2 and HDMX Proteins in Human Cancer. Hároníková L; Vojtěšek B Klin Onkol; 2018; 31(Suppl 2):63-70. PubMed ID: 31023026 [TBL] [Abstract][Full Text] [Related]
8. Mechanistic validation of a clinical lead stapled peptide that reactivates p53 by dual HDM2 and HDMX targeting. Wachter F; Morgan AM; Godes M; Mourtada R; Bird GH; Walensky LD Oncogene; 2017 Apr; 36(15):2184-2190. PubMed ID: 27721413 [TBL] [Abstract][Full Text] [Related]
9. Alterations in gene expression and sensitivity to genotoxic stress following HdmX or Hdm2 knockdown in human tumor cells harboring wild-type p53. Heminger K; Markey M; Mpagi M; Berberich SJ Aging (Albany NY); 2009 Jan; 1(1):89-108. PubMed ID: 19946469 [TBL] [Abstract][Full Text] [Related]
10. p53 promotes its own polyubiquitination by enhancing the HDM2 and HDMX interaction. Medina-Medina I; Martínez-Sánchez M; Hernández-Monge J; Fahraeus R; Muller P; Olivares-Illana V Protein Sci; 2018 May; 27(5):976-986. PubMed ID: 29524278 [TBL] [Abstract][Full Text] [Related]
11. Understanding the interaction of 14-3-3 proteins with hDMX and hDM2: a structural and biophysical study. Srdanović S; Wolter M; Trinh CH; Ottmann C; Warriner SL; Wilson AJ FEBS J; 2022 Sep; 289(17):5341-5358. PubMed ID: 35286747 [TBL] [Abstract][Full Text] [Related]
12. Abrogation of Wip1 expression by RITA-activated p53 potentiates apoptosis induction via activation of ATM and inhibition of HdmX. Spinnler C; Hedström E; Li H; de Lange J; Nikulenkov F; Teunisse AF; Verlaan-de Vries M; Grinkevich V; Jochemsen AG; Selivanova G Cell Death Differ; 2011 Nov; 18(11):1736-45. PubMed ID: 21546907 [TBL] [Abstract][Full Text] [Related]
14. Elaboration of Non-naturally Occurring Helical Tripeptides as p53-MDM2/MDMX Interaction Inhibitors. Su A; Tabata Y; Aoki K; Sada A; Ohki R; Nagatoishi S; Tsumoto K; Wang S; Otani Y; Ohwada T Chem Pharm Bull (Tokyo); 2021 Jul; 69(7):681-692. PubMed ID: 33952867 [TBL] [Abstract][Full Text] [Related]
15. Hdm2 disrupts HdmX-mediated nuclear export of p53 by sequestering it in nucleus. Ni Y; Chen H; Cheng X; Sun B; Wu Z; Zhan Q; Zhuang Z Exp Cell Res; 2024 Aug; 441(2):114185. PubMed ID: 39069150 [TBL] [Abstract][Full Text] [Related]
16. Levels of HdmX expression dictate the sensitivity of normal and transformed cells to Nutlin-3. Patton JT; Mayo LD; Singhi AD; Gudkov AV; Stark GR; Jackson MW Cancer Res; 2006 Mar; 66(6):3169-76. PubMed ID: 16540668 [TBL] [Abstract][Full Text] [Related]
17. HdmX stimulates Hdm2-mediated ubiquitination and degradation of p53. Linares LK; Hengstermann A; Ciechanover A; Müller S; Scheffner M Proc Natl Acad Sci U S A; 2003 Oct; 100(21):12009-14. PubMed ID: 14507994 [TBL] [Abstract][Full Text] [Related]
18. In vivo activation of the p53 tumor suppressor pathway by an engineered cyclotide. Ji Y; Majumder S; Millard M; Borra R; Bi T; Elnagar AY; Neamati N; Shekhtman A; Camarero JA J Am Chem Soc; 2013 Aug; 135(31):11623-11633. PubMed ID: 23848581 [TBL] [Abstract][Full Text] [Related]
19. Beta-peptides with improved affinity for hDM2 and hDMX. Harker EA; Daniels DS; Guarracino DA; Schepartz A Bioorg Med Chem; 2009 Mar; 17(5):2038-46. PubMed ID: 19211253 [TBL] [Abstract][Full Text] [Related]
20. Identification of a Small Molecule That Overcomes HdmX-Mediated Suppression of p53. Karan G; Wang H; Chakrabarti A; Karan S; Liu Z; Xia Z; Gundluru M; Moreton S; Saunthararajah Y; Jackson MW; Agarwal MK; Wald DN Mol Cancer Ther; 2016 Apr; 15(4):574-582. PubMed ID: 26883273 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]